syros.com - Multiplikator EV/Sales SYRS

Syros Pharmaceuticals (SYRS) is developing a gene control system for the treatment of cardiac and oncological pathologies. This chart in the GURU.Markets terminal illustrates the company's enterprise value to revenue (EV/Revenue) valuation, where the indicator determines the metric's magnitude. This price action reflects the stable operation of production lines and a strategic partnership with medical centers to develop targeted drugs against leukemia.
Rincian metrik keuangan lan pasar Syros Pharmaceuticals, Inc. (SYRS)

Developing precision medicines for leukemia therapy requires colossal investments, which is why the market value of Syros Pharmaceuticals (SYRS) is often decoupled from current earnings. This indicator compares the total enterprise value to revenue, excluding the impact of debt and leverage, allowing for an objective assessment of asset overvaluation and the risk of capital freeze through changes in the company's enterprise value-to-revenue multiple.